PA8447001A1 - Atropisomeros de 3- aril-4(3h)- quinazolinonas - Google Patents

Atropisomeros de 3- aril-4(3h)- quinazolinonas

Info

Publication number
PA8447001A1
PA8447001A1 PA19988447001A PA8447001A PA8447001A1 PA 8447001 A1 PA8447001 A1 PA 8447001A1 PA 19988447001 A PA19988447001 A PA 19988447001A PA 8447001 A PA8447001 A PA 8447001A PA 8447001 A1 PA8447001 A1 PA 8447001A1
Authority
PA
Panama
Prior art keywords
aril
quinazolinonas
atropisomeros
heteroaril
quinazolinones
Prior art date
Application number
PA19988447001A
Other languages
English (en)
Inventor
Welch Jr Willard Mckowan
Vries Keith Michael De
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PA8447001A1 publication Critical patent/PA8447001A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Adhesives Or Adhesive Processes (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVOS ATROPISOMEROS DE 2-(ARIL O HETEROARIL)-3 ARIL-4(3H)-QUINAZOLINONAS DE LA FORMULA I, A SUS SALES FARMACEUTICAS ACEPTABLES, Y A COMPOSICIONES FARMACEUTICAS Y PROCEDIMIENTOS PARA EL TRATAMIENTO DE AFECCIONES NEURODEGENERATIVAS Y RELACIONADAS CON TRAUMAS DEL SNC.
PA19988447001A 1997-02-28 1998-02-17 Atropisomeros de 3- aril-4(3h)- quinazolinonas PA8447001A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3890597P 1997-02-28 1997-02-28

Publications (1)

Publication Number Publication Date
PA8447001A1 true PA8447001A1 (es) 2000-05-24

Family

ID=21902563

Family Applications (1)

Application Number Title Priority Date Filing Date
PA19988447001A PA8447001A1 (es) 1997-02-28 1998-02-17 Atropisomeros de 3- aril-4(3h)- quinazolinonas

Country Status (40)

Country Link
US (1) US6306864B1 (es)
EP (1) EP0968194B1 (es)
JP (1) JP2000509731A (es)
KR (1) KR100358636B1 (es)
CN (1) CN1248248A (es)
AP (1) AP859A (es)
AR (1) AR011170A1 (es)
AT (1) ATE267817T1 (es)
AU (1) AU744028B2 (es)
BG (1) BG103689A (es)
BR (1) BR9807872A (es)
CA (1) CA2282277C (es)
DE (1) DE69824157T2 (es)
DK (1) DK0968194T3 (es)
DZ (1) DZ2440A1 (es)
EA (1) EA001963B1 (es)
ES (1) ES2219866T3 (es)
GT (1) GT199800038A (es)
HR (1) HRP980106A2 (es)
HU (1) HUP0000914A3 (es)
ID (1) ID22711A (es)
IL (1) IL130900A0 (es)
IS (1) IS1952B (es)
MA (1) MA24484A1 (es)
NO (1) NO313630B1 (es)
NZ (1) NZ336628A (es)
OA (1) OA11089A (es)
PA (1) PA8447001A1 (es)
PE (1) PE58399A1 (es)
PL (1) PL335418A1 (es)
PT (1) PT968194E (es)
SK (1) SK113299A3 (es)
TN (1) TNSN98035A1 (es)
TR (1) TR199902093T2 (es)
TW (1) TW504508B (es)
UA (1) UA61097C2 (es)
UY (1) UY24897A1 (es)
WO (1) WO1998038173A1 (es)
YU (1) YU41299A (es)
ZA (1) ZA981666B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100375155B1 (ko) 1996-05-15 2003-08-19 화이자 인코포레이티드 신규한2,3-이치환된-4(3에이치)-퀴나졸리논
US6323208B1 (en) 1997-09-05 2001-11-27 Pfizer Inc Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones
JPH11279158A (ja) * 1998-02-09 1999-10-12 Pfizer Prod Inc キナゾリン―４―オン誘導体の製造方法
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
SI2223922T1 (sl) * 2000-04-25 2016-04-29 Icos Corporation Inhibitorji humane fosfatidil-inositol 3-kinazne delta izoforme
EP1300396B1 (en) 2000-06-12 2009-01-14 Eisai R&D Management Co., Ltd. 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
BRPI0113331B8 (pt) 2000-08-18 2021-05-25 Ajinomoto Kk derivados de fenilalanina ou seus sais parmaceuticamente aceitáveis, antagonista de integrina alfa 4, agente terapêutico ou agente preventivo para doenças inflamatórias, e, composição farmacêutica
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
US6939968B2 (en) * 2002-12-23 2005-09-06 Bristol-Myers Squibb Company Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives
US20080146562A1 (en) * 2003-08-08 2008-06-19 Ulysses Pharmaceutical Products Inc., Halogenated quinazolinyl nitrofurans as antibacterial agents
US7410974B2 (en) * 2003-08-08 2008-08-12 Ulysses Pharmaceutical Products, Inc. Halogenated Quinazolinyl nitrofurans as antibacterial agents
GB0325390D0 (en) * 2003-10-30 2003-12-03 Novartis Ag Organic compounds
KR101194176B1 (ko) 2003-12-22 2012-10-24 아지노모토 가부시키가이샤 신규한 페닐알라닌 유도체
HUE030950T2 (en) 2004-05-13 2017-06-28 Icos Corp Quinazolinones as 3-kinase delta inhibitors of human phosphatidylinositol
MY148809A (en) 2004-07-06 2013-05-31 Eisai R&D Man Co Ltd Crystals of 1,2-dihydropyridine compound and their production process
GB0416730D0 (en) * 2004-07-27 2004-09-01 Novartis Ag Organic compounds
WO2007056124A2 (en) 2005-11-04 2007-05-18 Hydra Biosciences, Inc. Compounds for modulating trpv3 function
EP2079739A2 (en) 2006-10-04 2009-07-22 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
WO2008140750A1 (en) * 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
CN101429166B (zh) * 2007-11-07 2013-08-21 上海特化医药科技有限公司 喹唑啉酮衍生物及其制备方法和用途
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
CA3092449A1 (en) 2008-11-13 2010-05-20 Gilead Calistoga Llc Therapies for hematologic malignancies
EP2411391A1 (en) 2009-03-24 2012-02-01 Gilead Calistoga LLC Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
MX2012000817A (es) 2009-07-21 2012-05-08 Gilead Calistoga Llc Tratamiento para desordenes del higado con inhibidores pi3k.
PE20141792A1 (es) 2012-03-05 2014-12-07 Gilead Calistoga Llc Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluor-3-fenilquinazolin-4(3h)-ona
CN103275086B (zh) * 2013-05-30 2015-04-15 温州大学 一种6-取代喹唑啉并喹唑啉酮化合物及其合成方法和用途
CA2934531C (en) 2013-12-20 2020-02-25 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
EP3083623A1 (en) 2013-12-20 2016-10-26 Gilead Calistoga LLC Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
US9533909B2 (en) 2014-03-31 2017-01-03 Corning Incorporated Methods and apparatus for material processing using atmospheric thermal plasma reactor
CN106459005A (zh) 2014-06-13 2017-02-22 吉利德科学公司 磷脂酰肌醇3‑激酶抑制剂
DE102014217021A1 (de) * 2014-08-27 2016-03-03 Skf Lubrication Systems Germany Ag Gehäuse für eine Vorrichtung zum dosierten Verteilen eines Mediums sowie eine Dosiereinrichtung zur Verwendung in dem Gehäuse
CN113226286B (zh) 2018-12-14 2024-08-20 卫材R&D管理有限公司 1,2-二氢吡啶化合物的水基药物制剂
CN115335050B (zh) 2020-01-29 2024-05-17 卡玛瑞制药有限公司 用于治疗皮肤病症的化合物和组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1195321B (de) * 1962-03-16 1965-06-24 Troponwerke Dinklage & Co Verfahren zur Herstellung von substituierten Chinazolon-(4)-derivaten
DE1670416A1 (de) * 1966-12-30 1971-02-11 Chem Fab Von Heyden Gmbh Muenc Verfahren zur Herstellung von aminosubstituierten Chinazolinonderivaten
GB1298603A (en) * 1970-04-06 1972-12-06 Karamchand Premchand Private Quinazolinone derivatives
US4183931A (en) * 1977-09-08 1980-01-15 Research Corporation 2-Ketoalkyl-4(3H)-quinazolinones
GB9022785D0 (en) * 1990-10-19 1990-12-05 Merck Sharp & Dohme Therapeutic agents
WO1992013535A1 (en) * 1991-02-06 1992-08-20 Research Corporation Technologies, Inc. Anticonvulsant substituted quinazolones
US5777271A (en) * 1996-01-18 1998-07-07 Commscope, Inc. Cable having an at least partially oxidized armor layer
KR100375155B1 (ko) * 1996-05-15 2003-08-19 화이자 인코포레이티드 신규한2,3-이치환된-4(3에이치)-퀴나졸리논

Also Published As

Publication number Publication date
JP2000509731A (ja) 2000-08-02
TR199902093T2 (xx) 1999-12-21
ZA981666B (en) 1999-08-27
KR100358636B1 (ko) 2002-10-31
NO313630B1 (no) 2002-11-04
AP9801199A0 (en) 1998-03-31
AU744028B2 (en) 2002-02-14
IS1952B (is) 2004-10-13
ID22711A (id) 1999-12-09
NO994177D0 (no) 1999-08-27
PE58399A1 (es) 1999-06-16
IS5140A (is) 1999-07-30
AU5676898A (en) 1998-09-18
NZ336628A (en) 2001-03-30
EA199900693A1 (ru) 2000-02-28
PL335418A1 (en) 2000-04-25
ES2219866T3 (es) 2004-12-01
NO994177L (no) 1999-08-27
MA24484A1 (fr) 1998-10-01
EP0968194B1 (en) 2004-05-26
SK113299A3 (en) 2001-05-10
BR9807872A (pt) 2000-03-21
EA001963B1 (ru) 2001-10-22
TNSN98035A1 (fr) 2005-03-15
HRP980106A2 (en) 1999-02-28
TW504508B (en) 2002-10-01
AR011170A1 (es) 2000-08-02
UA61097C2 (uk) 2003-11-17
EP0968194A1 (en) 2000-01-05
DE69824157T2 (de) 2004-10-14
YU41299A (sh) 2002-09-19
CA2282277A1 (en) 1998-09-03
CA2282277C (en) 2005-10-11
CN1248248A (zh) 2000-03-22
HUP0000914A2 (hu) 2001-04-28
HUP0000914A3 (en) 2001-09-28
GT199800038A (es) 1999-08-13
BG103689A (bg) 2000-11-30
UY24897A1 (es) 2000-12-29
DZ2440A1 (fr) 2003-01-11
DE69824157D1 (de) 2004-07-01
IL130900A0 (en) 2001-01-28
WO1998038173A1 (en) 1998-09-03
PT968194E (pt) 2004-08-31
OA11089A (en) 2003-09-22
US6306864B1 (en) 2001-10-23
KR20000075814A (ko) 2000-12-26
DK0968194T3 (da) 2004-08-16
ATE267817T1 (de) 2004-06-15
AP859A (en) 2000-07-21

Similar Documents

Publication Publication Date Title
PA8447001A1 (es) Atropisomeros de 3- aril-4(3h)- quinazolinonas
GT199700049A (es) Nueva 4(3h)-quinazolinonas 2,3 disustituidas
DE50310516D1 (de) Fredericamycin-derivate
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
UY26782A1 (es) Derivados del benzotiazol
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
HN2001000224A (es) Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
DE50010931D1 (de) Substituierte benzimidazole
ATE355278T1 (de) Isochinolinon derivate als parp inhibitoren
PA8469401A1 (es) Derivados biciclicos del acido hidroxamico
PT1193270E (pt) Pirrolobenzodiazepinas
PA8578601A1 (es) Derivados de 2,2- difenil-benzodioxol
BR0109703A (pt) Derivados de piperazina
ES2421948T3 (es) Compuestos y composiciones para suministrar agentes activos
SE9802208D0 (sv) Novel compounds
PA8446901A1 (es) Atropisomeros de 3-heteroaril-4(3h)-quinazolinonas
DE60233350D1 (de) IMIDAZOi2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES
BR0213037A (pt) Derivados de pirimidina
DE60112960D1 (de) Kondensierte pyridoindolderivate
ES2193065T3 (es) Nueva utilizacion del saredutant.
SE9801494D0 (sv) Novel use
IT1318667B1 (it) Medicamento antinfiammatorio.
SE9802209D0 (sv) Novel compounds
AR023452A1 (es) Utilizacion del osanetant para preparacion de medicamentos utiles en el tratamiento de los trastornos del humor
HN2001000119A (es) S-metil-dihidro -ziprasidona para el tratamiento de trastornos psiquiatricos y oculares.